In T cells of SLE patients, mTOR activation triggers ROS production, while SIRT2 concurrently upregulates IL-17A expression in these cells by modulating the mTOR complex 1 (mTORC1)/HIF-1α/RORγt signaling pathway, thereby contributing to the pathogenesis of SLE (101, 155). This evidence concerns the gene IL17A and systemic lupus erythematosus.